Cases 21 - 30 of 141
Amgen Inc. v. Amneal Pharmaceuticals et al
as 1:2016cv00853
Defendant:
Aurobindo Pharma Ltd, Cadila Healthcare Ltd. doing business as Zydus Cadila, Hetero USA Inc. and others
Plaintiff:
Amgen Inc.
3Rd Party Defendant:
Alkem Laboratories Ltd. and Ascend Laboratories, LLC
Counter Claimant:
Cadila Healthcare Ltd.
Cause Of Action: 35 U.S.C. § 271
Bausch Health Ireland Limited et al v. Mylan Laboratories Ltd. et al
as 1:2021cv00611
Plaintiff:
Bausch Health Ireland Limited and Salix Pharmaceuticals, Inc.
Defendant:
Agila Specialties Inc., Mylan Pharmaceuticals Inc., Mylan Inc. and others
Cause Of Action: 35 U.S.C. § 1
Pfizer Inc. et al v. Mylan Pharmaceuticals Inc. et al
as 1:2020cv01395
Plaintiff:
Pfizer Inc., Warner-Lambert Company LLC and PF PRISM IMB B.V.
Defendant:
Mylan Pharmaceuticals Inc. and Mylan Inc.
Cause Of Action: 35 U.S.C. § 271
Novartis Pharmaceuticals Corporation v. Mylan Pharmaceuticals Inc. et al
as 1:2020cv00445
Plaintiff:
Novartis Pharmaceuticals Corporation
Defendant:
Mylan Pharmaceuticals Inc., Mylan Inc. and Mylan Laboratories Limited
Cause Of Action: 35 U.S.C. § 271
Merck Sharp & Dohme Corp. v. Mylan Pharmaceuticals Inc. et al
as 1:2019cv01489
Defendant:
Mylan Pharmaceuticals Inc.
Plaintiff:
Merck Sharp & Dohme Corp.
Cause Of Action: 35 U.S.C. § 271
In re: Palbociclib Patent Litigation
as 1:2019md02912
Not Classified By Court:
Aizant Drug Research Solutions Pvt. Ltd., Hetero USA Inc., Teva Pharmaceuticals USA, Inc. and others
In Re:
In re: Palbociclib Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Keryx Biopharmaceuticals, Inc et al v. Mylan Pharmaceuticals Inc.
as 1:2019cv01445
Plaintiff:
Panion & BF Biotech, Inc., Keryx Biopharmaceuticals, Inc. and Chen Hsing Hsu
Defendant:
Mylan Pharmaceuticals Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Auryxia (Ferric Citrate) Patent Litigation
as 1:2019md02896
Not Classified By Court:
Chemo Research S.L., Insud Pharma S.L., Teva Pharmaceuticals USA, Inc. and others
Counter Defendant:
Keryx Biopharmaceuticals, Inc., Panion & BF Biotech, Inc. and Chen Hsing Hsu
Counter Claimant:
Lupin Atlantis Holdings SA and Lupin Ltd.
In Re:
In re: Auryxia (Ferric Citrate) Patent Litigation
Cause Of Action: 35 U.S.C. § 271
Takeda Pharmaceuticals U.S.A., Inc. v. Mylan Pharmaceuticals Inc.
as 1:2019cv02216
Defendant:
Mylan Pharmaceuticals Inc.
Plaintiff:
Takeda Pharmaceuticals U.S.A., Inc.
3Rd Party Defendant:
Hikma Pharmaceuticals International Limited and Hikma Pharmaceuticals USA Inc.
Intervenor:
Par Pharmaceutical Inc.
Cause Of Action: 35 U.S.C. § 271
In re: Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
as 1:2019md02884
Counter Claimant:
Glasshouse Pharmaceuticals Limited Canada
Not Classified By Court:
Taro Pharmaceuticals U.S.A., Inc., Aurobindo Pharma Limited, Zydus Pharmaceuticals (USA) Inc. and others
In Re:
Kerydin (Tavaborole) Topical Solution 5% Patent Litigation
Counter Defendant:
Anacor Pharmaceuticals, Inc.
Cause Of Action: 35 U.S.C. § 271
Disclaimer: Justia Dockets & Filings provides public litigation records from the federal appellate and district courts. These filings and docket sheets should not be considered findings of fact or liability, nor do they necessarily reflect the view of Justia.
